Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

cancer therapeutics

This page shows the latest cancer therapeutics news and features for those working in and with pharma, biotech and healthcare.

Boehringer Ingelheim and Covant to collaborate on cancer immunotherapies

Boehringer Ingelheim and Covant to collaborate on cancer immunotherapies

Boehringer Ingelheim and Covant Therapeutics have entered into an exclusive research collaboration and worldwide licensing agreement to develop new cancer immunotherapies. ... By partnering with Covant’s exceptional scientific team and powerful platform

Latest news

  • Moderna and Life Edit partner to accelerate gene editing therapies Moderna and Life Edit partner to accelerate gene editing therapies

    Moderna and Life Edit Therapeutics, an ElevateBio company, have entered into a strategic collaboration aimed at discovering and developing in vivo mRNA gene editing therapies for hard-to-treat diseases. ... Moderna’s partnership with Life Edit is not

  • Moderna and CytomX to partner in deal worth up to 1.2bn Moderna and CytomX to partner in deal worth up to 1.2bn

    Moderna and cancer-focused drug developer CytomX Therapeutics (CytomX) have announced a collaboration and licensing agreement to create investigational mRNA-based conditionally-activated therapies for a wide range of diseases. ... In November 2022, the

  • Sanofi and Innate Pharma expand cancer therapeutics collaboration Sanofi and Innate Pharma expand cancer therapeutics collaboration

    The partnership is aimed at exploring the potential of natural killer cells therapeutics in oncology. ... Sanofi and Innate Pharma (Innate) have announced an expansion of their cancer therapeutics collaboration, with Sanofi licensing Innate’s

  • Summit Therapeutics partners with Akeso in deal worth $5bn Summit Therapeutics partners with Akeso in deal worth $5bn

    Summit Therapeutics (Summit) has announced a definitive agreement of its partnership with Akeso in a deal worth up to $5bn to in-licence its breakthrough bispecific antibody, ivonescimab. ... Recently presented phase 2 study results showed the PD-1/ VEGF

  • AstraZeneca to acquire Neogene Therapeutics in $320m deal AstraZeneca to acquire Neogene Therapeutics in $320m deal

    The agreement will build the company’s pipeline of cell-based cancer treatments. ... In contrast, through Neogene’s approach, TCR-Ts can recognise intracellular targets, including cancer-specific mutations, thereby potentially unlocking targets

More from news
Approximately 2 fully matching, plus 100 partially matching documents found.

Latest Intelligence

  • Well-funded life sciences firms are making long-term progress – and their investors are too Well-funded life sciences firms are making long-term progress – and their investors are too

    antigen test for population screening using Affimer reagents that bind to the SARS-CoV-2 spike protein, but also accelerate and expand work on their pre| CISION pipeline of cancer therapeutics. ... This came a week after announcing that it expects

  • Switzerland: a life sciences hub Switzerland: a life sciences hub

    For example, over the last five years, Lundbeck acquired Prexton Therapeutics, Agilent acquired Genohm and Boehringer Ingelheim acquired Amal Therapeutics, focused on cancer immunotherapy and therapeutic cancer vaccines. ... The company has been using

  • 30 Women Leaders in UK Healthcare 30 Women Leaders in UK Healthcare

    She works mainly in the translational field, focusing on the design and construction of antibody-based therapeutics to hit specific cancer targets, and is part of a broader team at UCL ... Current projects include developing antibodies for use as cancer

  • Deal Watch June 2016 Deal Watch June 2016

    licence. 230. Moderna Therapeutics/ Merck &Co. mRNA-based personalised cancer vaccines; exclusive for Keytruda combinations (discovery). ... acquisition company. 105. Nektar Therapeutics/ Daiichi Sankyo Europe. Onzeald (etirinotecan pegol), long-acting

  • Pharma deals in September 2015 Pharma deals in September 2015

    This month saw Takeda form a partnership with Gencia to develop two mitochondrial agonists of the glucocorticoid receptor (MAGR) drugs for the treatment of cancer and inflammatory diseases. ... Licence. 213. California Cancer Centre (City of Hope).

More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest appointments

  • Storm Therapeutics strengthens its board Storm Therapeutics strengthens its board

    Workman currently serves The Institute of Cancer Researc h as its president and chief executive officer and has formerly served as head of the division of cancer therapeutics at Cancer Research ... world class cancer institute and being a founder of

  • Scancell appoints Dr Cliff Holloway as CEO Scancell appoints Dr Cliff Holloway as CEO

    Prior to this, he was chief executive officer and managing director of Sienna Cancer Diagnostics, and has held roles for Immune System Therapeutics and Biosceptre International. ... John Chiplin, executive chairman, Scancell, said: “Cliff’s extensive

  • Revolution Medicines appoints Dr Stephen Kelsey Revolution Medicines appoints Dr Stephen Kelsey

    Most recently president at Onkaido Therapeutics, Kelsey’s specialty lies within oncology and development. ... I’m impressed with the quality of the company’s research team, founders and advisors, and am keen to help bring the next generation of

  • Crescendo Biologics appoints CFO Crescendo Biologics appoints CFO

    She joins from PsiOxus Therapeutics where she served as chief financial officer, and has also held a number of positions at Cytomyx Holdings, OrthoMimetics, and Mission Therapeutics. ... ambitious plans to create a high value pipeline of differentiated

  • MISSION appoints Paul Wallace as chief business officer MISSION appoints Paul Wallace as chief business officer

    Cancer biotech MISSION Therapeutics has named Paul Wallace as chief business officer. ... Our core focus is cancer, but our platform discovery approach has yielded highly promising molecules for other indications, such as Parkinson's disease.

More from appointments
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

The speed of science and the pace of comms
Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
Improving cardiovascular disease care and awareness
Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
Virtual Patient Engagement Program: A Customer Story
Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......

Quick links